Related Experiment Video
Updated: Feb 10, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
The Changing Treatment Landscape for Metastatic Urothelial Carcinoma
1Presented by Thomas W. Flaig, MD, University of Colorado Cancer Center, Aurora, Colorado.
Abstract:
Urothelial carcinoma is the predominant histologic type of bladder cancer. After 30 years of minimal progress in the treatment of advanced-stage disease, recent advances in the genomic characterization of urothelial cancer and breakthroughs in bladder cancer therapeutics have rejuvenated the field. Nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are among the exciting recent novel therapeutic advances gaining approvals by the FDA for treatment of advanced-stage urothelial carcinoma. Yet the challenge for clinicians is to determine the optimal choice of agents as first-line or second-line therapy and which offers the best chance for overall survival for the individual patient in this rapidly changing field.
Insights
Recent advances in urothelial carcinoma treatment offer new hope for advanced bladder cancer. The FDA has approved novel immunotherapies, but choosing the best option for patient survival remains a key challenge.
Area of Science:
- Oncology
- Urothelial Carcinoma Research
Background:
- Urothelial carcinoma is the most common type of bladder cancer.
- Treatment for advanced-stage disease has seen limited progress for decades.
- Recent genomic insights have revitalized the field of bladder cancer therapeutics.
Purpose of the Study:
- To review recent advances in urothelial carcinoma treatment.
- To highlight novel therapeutic agents approved for advanced-stage disease.
- To address the clinical challenge of selecting optimal therapies for individual patients.
Main Methods:
- Review of recent FDA-approved immunotherapies for urothelial carcinoma.
- Analysis of therapeutic advances in advanced bladder cancer.
- Discussion of clinical decision-making for first-line and second-line treatments.
Main Results:
- Nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are newly approved FDA agents.
- These novel therapies represent significant breakthroughs in treating advanced urothelial carcinoma.
- The field is rapidly evolving with new treatment options.
Conclusions:
- Recent therapeutic advances have rejuvenated the treatment landscape for advanced urothelial carcinoma.
- Optimal selection of novel immunotherapies is crucial for improving patient survival.
- Further research is needed to guide personalized treatment strategies in this dynamic field.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
Related Concept Videos
Global Climate Change
Rates of Change
Work Done During Volume Change
Consider a gas confined to a cylinder fitted with a movable piston at one end. If the gas expands from volume V1 to volume V2, it exerts a force on the piston, such that the piston moves by a distance dr.
The work done by the gas on the piston can be expressed as
Le Chatelier's Principle: Changing Temperature
To understand this phenomenon, consider the elementary reaction:
Standard Entropy Change for a Reaction
Unsoundness of Aggregate due to Volume Change